The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome
Status:
Not yet recruiting
Trial end date:
2030-12-31
Target enrollment:
Participant gender:
Summary
A multicenter, randomized, placebo-controlled, double-blind, phase III clinical trial will be
conducted to explore the efficacy and safety of mecobalamin in the prevention of 2/3 HFS in
patients with early breast cancer. 234 patients will be enrolled and will be randomized into
mecobalamin group and placebo group at the ration of 1:1. The incidence of grade 2 / 3 HFS in
the experimental group and the control group will be observed. This study is expected to
provide evidence for clinical prevention of hand foot syndrome, improve clinical treatment
guidelines for early breast cancer, and provide reference for other antitumor drugs for hand
foot syndrome.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University